LOWER MORTALITY WITH ADJUVANT CORTICOSTEROID THERAPY IN NON-HIV INFECTED PATIENTS WITH PNEUMOCYSTIS JIROVECII PNEUMONIA: A SINGLE US COHORT STUDY AND PROPOSED NOVEL MECHANISM OF CORTICOSTEROIDS

William Mundo, Leland Shaprio, Steven C. Johnson, Carlos Franco-Paredes, Andrés F. Henao-Martínez University of Colorado – Denver, Anschutz Medical Campus hivma Anschutz Medical Campus



University of Colorado

William.mundo@cuanschutz.edu

INTRODUCTION

- *Pneumocystis jiroveci* pneumonia (PJP) remains a source of mortality among immunocompromised hosts, including HIV negative patients
- Clinical features and benefits of corticosteroids as an adjuvant treatment are unclear in this population
- Aim: To characterize clinical features and identify predictors associated with mortality in a cohort of PJP cases.

METHODS

- Retrospective cohort study
- Setting: academic tertiary care center
- Timeline: 1995 to 2019 \bullet
- Population: individuals with laboratoryconfirmed (positive culture or antigen test) PJP disease
- Data source: Epic chart review
- Adjusted multivariable models \bullet

RESULTS

- Common underlying conditions in HIV negative patients were hematologic malignancies (28.6%), autoimmune disorders (25.9%), and organ transplants (10.7%).
- Mortality was significantly associated with HIV negative status (OR 11.0, 95% CI: 1.5-81.3, p<0.018) and absence of corticosteroids for adjuvant treatment (OR 13.8, 95% CI: 1.2-159.2, p<0.036).

RESULTS

TABLE 1: Clinical features of Pneumocystis jiroveciipneumonia patient cases with HIV and non-HIV status.			
	HIV (n=43)	Non-HIV (n=28)	p-value
Mean age (±SD, years)	49.12 ± 10.97	62.07 ± 13.66	<0.001
Male sex (%)	38 (88.37)	15 (53.57)	0.001
white (%)	31 (72.09)	23 (82.14)	0.853
Non-white Hispanic (%)	11.5 (25.58)	4 (14.29)	0.009
Mean Hemoglobin (±SD, mg/dL)	12.98 ± 2.25	10.9 ± 2.24	0.001
Mean, Platelets (±SD, mg/dL)	271.36 ± 127.86	141.28 ± 85.13	<0.001
Corticosteroids (%)	37 (86.05)	20 (71.43)	0.13
ICU Admission (%)	10 (23.26)	22 (78.57)	<0.001
Mortality (%)	7 (16.28)	20 (71.43)	<0.001
% of PIP Case Mortality by HIV Status and Use of			

% of PJP Case Mortality by HIV Status and Use of **Corticosteroid Adjuvant Therapy**






Figure 1. Proportion of Mortality in PJP cases by HIV Status and Corticosteroids

Open Forum Infectious Diseases

1AJOR ARTICLE

Compared to individuals with HIV, non-**HIV PJP patients and absence of** corticosteroid as adjuvant therapy increased rates of mechanical ventilation, ICU stay and mortality.




Figure 2. Proposed novel corticosteroid mechanism in PJP infections

Conclusions

- Difference in mortality in PJP is attributed to the severity of presentation, comorbidities, and multiorgan injury
- Further studies are needed on prevention, early diagnosis, and management of PJP among HIV negative patients